8-K
filed October 17, 2025, 7:59 PM ET
ticker RVPH
CIK 0001742927
regulatory
confidence high
sentiment neutral
materiality 0.55
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH): Nasdaq/NYSE listing notice — Reviva regains Nasdaq MVLS compliance; still faces bid price delisting risk by Nov 10
REVIVA PHARMACEUTICALS HOLDINGS, INC.
- Received Nasdaq letter on Oct 14 confirming compliance with $35M minimum market value of listed securities requirement; matter closed.
- Remains non-compliant with $1.00 minimum bid price rule; initial cure period ends November 10, 2025.
- May consider reverse stock split to regain bid price compliance; no assurance of success.
- Previous MVLS non-compliance resolved after 10 consecutive business days above $35M (Sept 30 to Oct 13).
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).
- Exchange
- nasdaq
- Notice
- compliance regained
- Deficiency
- market value
- Rules
- 5550(b)(2)
Exact text from the filing
October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) received a letter (the “MVLS Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) formally notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities (“MVLS”) requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) and that the MVLS Requirement matter is now closed. The MVLS Compliance Letter was pursuant to a previous notice received on Augu
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.